The U.S. drug of abuse testing services market size is anticipated to reach USD 1.29 billion by 2030, registering a CAGR of 4.65% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by several key factors, including rising substance abuse rates, stringent workplace safety regulations, and the growing need for compliance with federal and state mandates. Increasing adoption of pre-employment and random drug screening in industries like transportation, healthcare, and manufacturing is likely to propel the demand.
The ongoing opioid crisis has intensified the need for comprehensive drug testing services, with both government agencies and private organizations investing in expanded testing capabilities to address this public health emergency. In addition, the rise in recreational drug use, including cannabis, in several states, has increased the demand for testing solutions that can differentiate between legal and illegal substances, contributing to the market expansion.
The regulatory environment in the U.S. continues to support market growth, as stringent workplace drug testing policies and guidelines from organizations like SAMHSA and DOT ensure the widespread adoption of testing services. Employers across industries such as transportation, healthcare, and manufacturing are increasingly implementing drug testing protocols to comply with these regulations and ensure workplace safety. The introduction of new testing technologies, such as rapid testing kits, saliva-based tests, and mobile testing units, has further fueled market growth by providing more convenient, cost-effective, and accurate solutions for drug detection.
Technological innovation is also a major driver of market growth, as advancements in testing technologies are making drug testing more efficient, accurate, and accessible. The introduction of multiplex testing platforms and automation in laboratories has improved turnaround times and reduced human error, while artificial intelligence and machine learning applications offer enhanced data analysis capabilities for better decision-making. These innovations are attracting new market players and investors, fostering competition and further propelling market expansion. In addition, increasing acceptance of at-home drug testing kits and mobile testing services has broadened the market, appealing to both individuals and organizations seeking convenient, non-invasive solutions.
Some key players in the market are Omega Laboratories, Inc., Clinical Reference Laboratory (CRL), Inc., Millennium Health, LLC, Cordant Health Solutions, Psychemedics Corporation, Abbott, DrugScan, Quest Diagnostics, Legacy Medical Services, and Laboratory Corporation of America Holdings. Key players are focusing on new product launches to increase their market presence. For instance, In October 2023, Psychemedics Corporation revealed its Advanced 5- Panel Drug Screen, a U.S. FDA-cleared test designed to identify fentanyl. This new panel addresses the increasing prevalence of fentanyl and includes tests for PCP, cocaine, amphetamines, and opioids. It significantly improves accuracy, being 25 times more effective at detecting opioids, 23 times more for cocaine, and 13 times more for amphetamines compared to conventional tests.
Request a free sample copy or view report summary: U.S. Drug Of Abuse Testing Services Market Report
Based on drug, the cannabis/marijuana accounted for 57.32% revenue share in 2024. With legalization of cannabis in various states across the U.S, the illicit consumption of cannabis has been increasing across age groups. This is the major factor for the segment dominance within the U.S.
The growing prevalence of substance abuse, particularly opioids and synthetic drugs, has driven the need for expanded testing services in the U.S. This trend is further supported by rising public health concerns and efforts to combat the opioid crisis through early detection and intervention
Stringent regulatory mandates such as the Drug-Free Workplace Act and Department of Transportation (DOT) regulations have resulted in routine drug testing for safety-sensitive positions, contributing to high demand for testing services
Grand View Research has segmented the U.S. drug of abuse testing services market report based on the drug:
U.S. Drug Of Abuse Testing Services Drug Outlook (Revenue, USD Million, 2018 - 2030)
Alcohol
Cannabis/Marijuana
Cocaine
Opioids
Amphetamine & Methamphetamine
LSD
Others
List of Key Players in U.S. Drug Of Abuse Testing Services Market
Quest Diagnostics
Abbott
Clinical Reference Laboratory (CRL), Inc
Laboratory Corporation of America Holdings
Cordant Health Solutions
Legacy Medical Services
DrugScan
Omega Laboratories, Inc.
Psychemedics Corporation
Millennium Health, LLC
"The quality of research they have done for us has been excellent..."